Try our mobile app
A new post hoc sub-analysis of the landmark REDUCE-IT Study, published in the Journal of the American Heart Association (JAHA), found VASCEPA® significantly reduced the risk of cardiovascular death, strokes, heart attacks, coronary revascularization, and unstable angina by 34% in patients with a history of percutaneous coronary intervention (PCI).(1)
Icosapent ethyl resulted in robust absolute risk reductions of 8.5% and 5.4% and numbers needed to treat (NNT) of 12 and 19, respectively, for the primary and key secondary composite endpoints.(1)
DUBLIN, Ireland and BRIDGEWATER, N.J., March 10, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced the publication of new REDUCE-IT data analysis that helps support the clinical benefits of icosapent ethyl (IPE) for patients who have received a percutaneous coronary intervention (PCI) and are at high risk for experiencing a stroke, heart attack, or fatal cardiovascular (CV) event.(1)
Percutaneous coronary interventions (also known as coronary angioplasty, which can include stent insertion) are medical procedures used to open coronary arteries, the main blood vessels supplying the heart, that are narrowed or blocked by a build-up of atherosclerotic plaque.(2) The heart needs a constant supply of oxygenated blood to function effectively; if the coronary arteries become narrowed and restricted, this can lead to serious heart health complications such as angina or a heart attack.(3)
The REDUCE-IT Prior PCI study was a post hoc sub-analysis published in the Journal of the American Heart Association (JAHA). This publication furthers the clinical evidence base for icosapent ethyl treatment in patients with prior PCI at risk of a recurrent CV event.
There were 3,408 patients who had undergone a prior PCI (41.7% of the initial REDUCE-IT study population). The median time after PCI for these patients was 2.9 years. Baseline characteristics were similar among patients randomised to icosapent ethyl versus placebo. Of those patients with prior PCI included in the sub-analysis receiving standard of care treatment only, 37.6% experienced a major CV event (cardiovascular death, myocardial infarction, stroke, coronary revascularization, or unstable angina requiring hospitalization), compared with 25.6% of patients receiving icosapent ethyl.(1)
In patients with a history of PCI, icosapent ethyl treatment versus placebo reduced the first primary composite endpoint of CV death, non-fatal myocardial infarction (MI) (heart attack), non-fatal stroke, coronary revascularization, or unstable angina, by 34% (absolute risk reduction of 8.5%, HR 0.66; 95% CI, 0.58-0.76; p
